SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial
Article Information
vol. 70 no. 3 800-808
PubMed
Published By
Print ISSN
Online ISSN
History
- Received September 11, 2020
- Accepted December 14, 2020
- Published in print February 19, 2021.
- Published online ahead of print December 17, 2020.
Article Versions
- Previous version (December 17, 2020 - 14:35).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2021 by the American Diabetes Association https://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.
Author Information
- Katrine M. Lauritsen1,2,3,
- Bent R.R. Nielsen4,
- Lars P. Tolbod5,
- Mogens Johannsen6,
- Jakob Hansen6,
- Troels K. Hansen1,
- Henrik Wiggers4,
- Niels Møller1,2,
- Lars C. Gormsen5 and
- Esben Søndergaard1,2,3⇑
- 1Steno Diabetes Center, Aarhus, Denmark
- 2Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark
- 3Danish Diabetes Academy, Odense University Hospital, Odense, Denmark
- 4Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
- 5Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus Denmark
- 6Department of Forensic Medicine, Aarhus University, Aarhus, Denmark
- Corresponding author: Esben Søndergaard, esben.sondergaard{at}clin.au.dk
L.C.G. and E.S. contributed equally to the work.
Statistics from Altmetric.com
Article usage
In this Issue
March 2021, 70(3)
SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial
